New drug combo targets Hard-to-Treat lung cancer in early trial

NCT ID NCT07174583

Recruiting now Disease control Sponsor: IDEAYA Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study tests a new drug called IDE849, alone or with other drugs, in people with cancers that have a protein called DLL3, including small cell lung cancer. The trial has two phases and aims to see if the drug is safe and shrinks tumors. About 208 participants who have already tried standard treatments will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IDE849 (a drug given intravenously), sometimes combined with durvalumab (another IV drug) or IDE161 (an oral drug)
What this could lead to: If successful, this could point toward a new treatment option for small cell lung cancer and other DLL3-expressing tumors that have stopped responding to standard therapy.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 208 participants, so the drug may not prove effective or safe enough for wider use. Side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE CARCINOMAS SMALL CELL LUNG CANCER SOLID TUMOR SHOW TO EXPRESS DLL3

Contacts and locations

Locations

Columbia University Medical Center - Herbert Irving Pavilion
RECRUITING

New York, New York, 10032, United States
Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office
RECRUITING

Fort Wayne, Indiana, 46825-1623, United States
NEXT Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Next Oncology Dallas
RECRUITING

Irving, Texas, 75039, United States
Oncology Consultants, PA- Houston
RECRUITING

Houston, Texas, 77030, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
Sarah Cannon Research Institute - Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at Florida Cancer Specialists
RECRUITING

Orlando, Florida, 32827, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
Sidney Kimmel Cancer Center at Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Swedish Cancer Institute
RECRUITING

Seattle, Washington, 98104, United States
The Cancer and Hematology Centers
RECRUITING

Grand Rapids, Michigan, 49546, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030-4000, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.